Public Employees Retirement System of Ohio Makes New $72.22 Million Investment in Thermo Fisher Scientific Inc. $TMO

Public Employees Retirement System of Ohio bought a new stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm bought 144,058 shares of the medical research company’s stock, valued at approximately $72,225,000.

Other large investors also recently bought and sold shares of the company. Legacy Wealth Managment LLC ID lifted its position in shares of Thermo Fisher Scientific by 78.6% during the 1st quarter. Legacy Wealth Managment LLC ID now owns 50 shares of the medical research company’s stock valued at $25,000 after buying an additional 22 shares in the last quarter. Kilter Group LLC purchased a new stake in Thermo Fisher Scientific in the 2nd quarter worth $25,000. Allied Private Wealth LLC acquired a new position in Thermo Fisher Scientific during the second quarter worth $26,000. High Note Wealth LLC lifted its holdings in Thermo Fisher Scientific by 170.6% during the fourth quarter. High Note Wealth LLC now owns 46 shares of the medical research company’s stock valued at $27,000 after purchasing an additional 29 shares in the last quarter. Finally, JPL Wealth Management LLC acquired a new stake in shares of Thermo Fisher Scientific in the third quarter valued at about $28,000. Institutional investors and hedge funds own 89.23% of the company’s stock.

Thermo Fisher Scientific Stock Down 0.5%

Shares of TMO opened at $630.66 on Friday. Thermo Fisher Scientific Inc. has a 52-week low of $435.27 and a 52-week high of $647.00. The company has a quick ratio of 1.18, a current ratio of 1.55 and a debt-to-equity ratio of 0.74. The stock has a fifty day simple moving average of $555.52 and a two-hundred day simple moving average of $511.31. The company has a market capitalization of $233.18 billion, a PE ratio of 33.92, a price-to-earnings-growth ratio of 2.58 and a beta of 0.85.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings data on Thursday, July 23rd. The medical research company reported $6.03 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.71 by $0.32. Thermo Fisher Scientific had a net margin of 15.04% and a return on equity of 17.09%. The firm had revenue of $11.99 billion during the quarter, compared to analyst estimates of $11.71 billion. During the same quarter in the prior year, the firm posted $4.28 earnings per share. Thermo Fisher Scientific’s quarterly revenue was up 10.5% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. As a group, equities analysts forecast that Thermo Fisher Scientific Inc. will post 25.12 EPS for the current year.

Thermo Fisher Scientific Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Thursday, October 15th. Stockholders of record on Tuesday, September 15th will be issued a dividend of $0.47 per share. The ex-dividend date is Tuesday, September 15th. This represents a $1.88 dividend on an annualized basis and a dividend yield of 0.3%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is currently 10.11%.

Analyst Ratings Changes

TMO has been the subject of several research reports. Weiss Ratings upgraded Thermo Fisher Scientific from a “hold (c-)” rating to a “hold (c)” rating in a research note on Tuesday, July 14th. Sanford C. Bernstein began coverage on Thermo Fisher Scientific in a research note on Friday, June 26th. They issued a “market perform” rating and a $520.00 price objective for the company. KeyCorp reaffirmed an “overweight” rating on shares of Thermo Fisher Scientific in a report on Tuesday, May 26th. Piper Sandler increased their target price on shares of Thermo Fisher Scientific from $510.00 to $600.00 and gave the company a “neutral” rating in a research report on Monday, July 27th. Finally, Jefferies Financial Group restated a “buy” rating and set a $630.00 price target on shares of Thermo Fisher Scientific in a research report on Thursday, July 23rd. One research analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and six have issued a Hold rating to the company. According to MarketBeat, Thermo Fisher Scientific has an average rating of “Moderate Buy” and an average price target of $619.41.

Key Headlines Impacting Thermo Fisher Scientific

Here are the key news stories impacting Thermo Fisher Scientific this week:

• Positive Sentiment: Thermo Fisher introduced the Thermo Scientific EMPAD G2 electron detector, designed to enable faster, high-speed four-dimensional scanning transmission electron microscopy. The product could support demand for the company’s analytical-instrument portfolio and strengthen its position in advanced materials research. Thermo Fisher Scientific Introduces the EMPAD G2 Electron Detector
• Positive Sentiment: A recent analysis examines whether Isora could provide Thermo Fisher with an additional long-term growth opportunity, potentially broadening the company’s exposure to emerging research and laboratory markets. Can Isora Unlock a New Growth Edge?
• Neutral Sentiment: Thermo Fisher’s latest reported quarter showed solid momentum: adjusted EPS of $6.03 exceeded estimates, revenue reached $11.99 billion, and sales increased 10.5% year over year. Fiscal 2026 EPS guidance remains $24.93-$25.33, but much of this strength may already be reflected in the stock’s elevated valuation.
• Neutral Sentiment: Analyst sentiment remains favorable, with a consensus “Moderate Buy” rating, although the average price target of $619.41 is below recent trading levels. Several firms have raised targets toward $650, suggesting optimism but limited upside at the current valuation.
• Negative Sentiment: CEO Marc Casper sold 275 shares for approximately $172,000 after selling 10,000 shares worth about $6.3 million earlier in the month. Both transactions were executed under pre-arranged Rule 10b5-1 plans, reducing their significance as a signal of deteriorating fundamentals, but the sales can still weigh on sentiment.

Insider Activity

In related news, VP Lisa P. Britt sold 11,440 shares of the company’s stock in a transaction that occurred on Wednesday, August 19th. The stock was sold at an average price of $613.12, for a total value of $7,014,092.80. Following the transaction, the vice president directly owned 14,784 shares in the company, valued at approximately $9,064,366.08. This represents a 43.62% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Michael D. Shafer sold 25,500 shares of the firm’s stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $600.00, for a total value of $15,300,000.00. Following the sale, the executive vice president directly owned 20,994 shares of the company’s stock, valued at approximately $12,596,400. This trade represents a 54.85% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 73,768 shares of company stock worth $44,122,820 in the last 90 days. 0.33% of the stock is owned by corporate insiders.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.